Investors have long known that there can be huge money in rare diseases, and over the years they have rewarded stocks like Genzyme (now part of Sanofi (SNY)) and Alexion (ALXN) accordingly. As another player in the rare disease space, BioMarin (BMRN) already sports a nearly $4 billion market cap, but with a lot of key clinical data coming in the next few quarters, it's worth exploring how much more could be left in the tank.
The Businesses In Hand
BioMarin is a somewhat rare biotech in that it already has four drugs approved and on the market.
Read the complete article here:
How Much Further Can Rare Diseases Carry BioMarin?
No comments:
Post a Comment